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Merkelcellcarcinomaisarare,buthighlymalignanttumoroftheskinwithhighratesofmetastasisandpoorsurvival.Itsincidence
rate rises and is currently about 0.6/100000/year. Clinical diﬀerential diagnoses include basal cell carcinoma, cyst, amelanotic
melanoma, lymphoma and atypical ﬁbroxanthoma. In this review article clinical, histopathological and immunhistochemical
features of Merkel cell carcinoma are reported. In addition, the role of Merkel cell polyomavirus is discussed.
1.Introduction
Merkel cell carcinoma (MCC) is one of the most malignant
tumors of the skin which aﬀects primarily sun-exposed skin
from older Caucasian, predominantly males with a mean age
at the time of diagnosis of about 70 years [1]. Its incidence
rate rises with immunosuppression [2, 3], and is currently
0.6/100000/year [4]. Its biological behavior is highly aggres-
sive with high rates of metastasis and poor survival [1]. If
the Merkel cell is the cell of origin of this cancer is still
matter of debate. Recently, it was reported that Merkel cells
are derived from the epithelial lineage [5]. Besides, because
of sarcomatous elements were found in MCC, so a totipotent
epithelial stem cell as origin was suggested [6], but further
examinations are requested.
2.ClinicalFeatures
MCC characteristically develops rapidly and asymptomati-
cally over months [7]. Most MCCs are located on sun-ex-
posed areas. About 50% of MCCs occur on the head and
neck, 40% on the extremities and remainder on the trunk
and genitalia [8]. It very rarely arises on sun-protected areas,
such as the oral and genital mucous membranes, where it
is characterized by a particularly poor prognosis [9, 10].
Itusuallymanifestsassolitary,ﬁrm,ﬂesh-coloredtorednod-
ule with a smooth, shiny surface, sometimes with telangiec-
tasia [11, 12]. Diﬀerential diagnosis includes basal cell car-
cinoma, cyst, amelanotic melanoma, lymphoma, and atyp-
ical ﬁbroxanthoma [13].
The ﬁve most common clinical features were used to cre-
ate an acronym AEIOU [14];
Asymptomatic/lack of tenderness,
Expanding rapidly (≤3 months),
Immunosuppression,
Older than age 50,
UV-exposed site.
3.Histopathology
MCC usually appears as a dermal tumor nodule, which
frequently extends into the subcutaneous fatty tissue. The
tumor cells are small blue cells with basophilic nuclei and
minimal cytoplasm. Mitoses are frequent and the apoptosis
index is high [15]. The papillary dermis and adnexa are
usually spared [16].2 Journal of Skin Cancer
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Figure 1: (a) Small-cell variant, histologically indistinguishable from bronchial small-cell carcinoma. (b) Intermediate variant of MCC
showing vesicular, basophilic nuclei with prominent nucleoli and high mitotic activity. (c) Trabecular variant is rare and normally only seen
as a small component of a mixed variant.
Three histologic subtypes (showen by Figure 1)h a v e
been recognized [4]:
(a) the intermediate type,
(b) the small cell type,
(c) the trabecular type.
In the latest data the trabecular form is discussed as the best
diﬀerentiated with a better prognosis, while the small cell
form is relatively undiﬀerentiated and has a worse prognosis.
But comprehensive data are missing and mixed and tran-
sitional forms are frequent, so there is no clear histologic-
prognostic association.
Tumor size ≤2cm,femalegender,primarytumourlocal-
ized at the upper limb, and pathologically proven negative
lymph nodes are factors highly signiﬁcant for prognosis and
are incorporated into the new staging system for MCC [6,
19].
Andea et al. evaluated retrospectively the following
histologicfeatureswithregardtoprognosis:tumorthickness,
microanatomic compartment involved by tumor (dermis
and/or subcutis and/or deeper), tumor growth pattern (nod-
ular circumscribed versus inﬁltrative), lymphovascular inva-
sion, tumor-inﬁltrating lymphocytes, tumor necrosis, ulcer-
ation, and solar elastosis. On multivariate analysis, tumor
thickness, the presence of a nodular growth pattern, low
tumor depth and absence of lymphovascular invasion were
statistically signiﬁcantly associated with longer survival [20].
Morphometric analyses revealed that Merkel cell polyo-
mavirus-negative Merkel cell carcinomas show a diﬀerent
histologic appearance with more irregular nuclei and more
abundant cytoplasm than Merkel cell polyomavirus-positive
Merkel cell carcinomas, which are characterized by uniform
round nuclei and scant cytoplasm [21].
4. Immunohistochemistry
The “small round blue cell” histologic pattern of MCC must
be diﬀerentiated from several other tumors, such as small-
cell lung carcinoma, carcinoid tumor, malignant lymphoma,
and small-cell melanoma. Therefore immunohistochemical
stainings are required. MCCs are positive for epithelial and
neuroendocrine markers, but are negative for lymphoid
and melanoma markers [15]. Table 1 shows characteristic
immunohistochemical staining patterns for these entities.
Positive staining for CK20 and NSE are quite speciﬁc
for MCC. Anti-cytokeratin 20 (CK20) staining is concordant
to data from the previous literature showing “paranuclear
dot-like pattern” in 97% of all included MCCs [7]. This
highly sensitive staining feature is very important for routine
histopathology to distinguish MCCs from other small round
blue cell tumors [22, 23].
Thyroid transcription factor-1 (TTF-1) is usually ex-
pressed in small-cell lung carcinoma but is consistently
absent in MCC [7]. Leucocyte common antigen (LCA) is
negative in MCC, but positive in lymphoma [18, 24]. Small
cell carcinoma of the lung (SCLC) is cytokeratin 7 (CK7)
positive, but not MCC [22].
Another useful marker for the distinction between MCC
and small-cell lung carcinoma is the neuroﬁlament protein
(NFP), which is usually positive in MCC and always negative
in small-cell lung carcinoma [22].
The diﬀerentiation between MCC and malignant
melanoma is based on the negativity of the latter for CK 20
and its positivity for HBM45, NKI/C3, and S-100, for which
MCC is usually negative [25].
Further, the tumor cells of MCC display additional
antigens in varying frequency and intensity; these include,
among others, chromogranin A, synaptophysin, tenascin-C,
CD56 as well as various neuroﬁlaments and neuropeptides.
Expression of the inhibitor of apoptosis (IAP) survivin and
the member of the p53 family p63 appears to be associated
with a poorer prognosis [17, 26–28].
5.MerkelCellPolyomavirus
Although MCC is one of the most aggressive skin cancers
witha high mortality rate, little is known about potential sig-
nalling mechanism that drives carcinogenesis in MCC. The
association of MCC with immunosuppression has prompted
the hypothesis of a viral implication in the pathogenesis
of the tumor. But the published data on the impact ofJournal of Skin Cancer 3
Table 1: Immunohistochemistry of Merkel cell carcinoma (according to Schrama et al. 2011, Becker et al. 2008; [17, 18]). CK20: cytokeratin
20; CK7: cytokeratin 7; NSE: neuron-speciﬁc enolase; TTF1: thyorid transcriptor factor 1; LCA: leucocyte common antigen.
CK20 CK7 NSE TTF1 S100 LCA
Merkel cell carcinoma (MCC) + − + −−−
Small cell carcinoma of the lung
(SCLC)
− +++−−
Melanoma −−−−+ −
Lymphoma −−−−−+
Merkelcellpolyomavirus(MCPyV)presenceorviralloadon
prognosis remain controversial.
Merkel cell Polyomavirus (MCPyV) was identiﬁed in
January 2008 by Feng and colleagues in tumor tissue from
MCC patients, proving clonal integration of the virus DNA
into the host genome [25]. Meanwhile several studies con-
ﬁrmed this observation showing frequent prevalence of
MCPyV DNA in MCCs [29–35]. These data suggest MCPyV
as the likely causative agent of MCC. It is supposed that an
interaction of the MCC virus protein with p53 and members
of the retinoblastoma (Rb-) Gen family could be responsible
for the malignant degradation [30, 36].
Furthermore, Sihto et al. found evidence for better
prognosis in MCPyV DNA-positive MCC having fewer
regional nodal metastasis at time of diagnosis compared
to MCPyV DNA-negative MCC [34]. Andres et al. showed
that MCPyV DNA-positive MCCs tend to be preferentially
located on the limbs and tend to metastasize less frequently
[37]. It seems that MCPyV MCCs harbour more genomic
aberrations than MCPyV ones [38]. Besides it has been re-
ported that absence of MCPyV or lower viral abundance is
associated with increased p53 and KIT espression [39, 40].
Meanwhile, latest data did not show better clinical prognosis
in patients with MCPyV-positive MCCs [2, 25].
6. CK20-, CK19-, CD117-, andST-3 Protein
Expressionof Tumor Cells as a Function
of Presence of MCPyV DNA in MCC
There is only one report analyzing immunohistochemical
features of MCCs in correlation to presence of MCPyV
DNA [41]. In the cohort studied there is no statistical
signiﬁcantassociationbetweenMCPyVDNAprevalenceand
immunohistochemical expression of CK20, CK19, CD117,
and ST3 was detected but some exciting trends.
CK 19 is a small human cytokeratin, expressed in un-
diﬀerentiated germinative basaloid cells and usually not ex-
pressedbycellsofnonepithelialorigin[42].CD117isatrans-
membrane protein of the receptor tyrosine kinase family.
Stromeylsin-3/matrix metalloproteinase11 (ST3) overex-
pression could be associated with tumor invasion because of
a antiapoptotic eﬀects [43]. A more frequent CK19 expres-
sion in MCPyV DNA-negative MCCs and CD117 expression
in MCPyV DNA-positive MCCs was observed. Moreover,
CK19 is a helpful diagnostic marker for CK20-negative
MCC. The role of ST3 expression is not yet clear, being ex-
pressed by the MCC tumor cells themselves in about half of
all cases,independent of MCPyV DNA-prevalence.However,
in some studies MCPyV DNA-prevalence seems to inﬂuence
the biological behavior of MCCs, resulting in better overall
survival for patients with positive MCPyV DNA-status [34].
Most probably due to diﬀerent invasion and metastatic
properties, Andres et al. were not able to ﬁnd statistically
signiﬁcant diﬀerences in the expression pattern of CK20,
CK19, CD117, and ST3 [41].
In conclusion, more data will be needed to get profound
insight in the carcinogenesis of MCC. As MCC is a rare
cancer, studies are limited and further molecular studies are
required as well as clinical investigations to establish the
impact of MCPyV on MCC which perhaps could open new
therapetic options.
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